$AVIR

Atea Pharmaceuticals, Inc.

CIK:0001593899|SEC Filings

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Operating expenses:
Research and development	$ 28,150	$ 32,275	$ 69,284	$ 61,859
General and administrative	6,949	9,070	13,823	18,527
Total operating expenses	35,099	41,345	83,107	80,386
Loss from operations	(35,099)	(41,345)	(83,107)	(80,386)
Interest income and other, net	2,190	4,391	4,808	9,363
Loss before income taxes	(32,909)	(36,954)	(78,299)	(71,023)
Income tax expense	(24)	(207)	(74)	(410)
Net loss	(32,933)	(37,161)	(78,373)	(71,433)
Other comprehensive loss
Unrealized gain (loss) on available-for-sale investments	1	(81)	(270)	(196)
Comprehensive loss	$ (32,932)	$ (37,242)	$ (78,643)	$ (71,629)
Net loss per share - basic and diluted
Net loss per share - basic	$ (0.41)	$ (0.44)	$ (0.99)	$ (0.85)
Net loss per share - diluted	$ (0.41)	$ (0.44)	$ (0.99)	$ (0.85)
Weighted-average number of common shares - basic and diluted
Weighted-average number of common shares - basic	80,050,518	83,747,335	79,183,301	84,449,318
Weighted-average number of common shares - diluted	80,050,518	83,747,335	79,183,301	84,449,318

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025
Cash flows from operating activities
Net loss	$ (78,373)	$ (71,433)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense	7,110	11,618
Depreciation and amortization expense	208	208
Accretion of premium and discounts on marketable securities	(1,123)	(3,061)
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(39)	1,743
Other assets	88	(4,197)
Accounts payable	(2,887)	4,386
Accrued expenses and other liabilities	(8,354)	(2,602)
Operating lease liabilities	(105)	(95)
Net cash used in operating activities	(83,475)	(63,433)
Cash flows from investing activities
Purchases of marketable securities	(108,356)	(223,368)
Sales and maturities of marketable securities	172,409	324,266
Net cash provided by investing activities	64,053	100,898
Cash flows from financing activities
Proceeds from issuance of common stock upon exercise of stock options	871
Proceeds from issuance of common stock under employee stock purchase plan	132	138
Repurchase of common stock		(14,093)
Issuance of restricted stock units	(746)	(485)
Net cash provided by (used in) financing activities	257	(14,440)
Net (decrease) increase in cash and cash equivalents	(19,165)	23,025
Cash and cash equivalents at the beginning of period	95,713	64,696
Cash and cash equivalents at the end of period	$ 76,548	$ 87,721

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2026	Dec. 31, 2025
Current assets
Cash and cash equivalents	$ 76,548	$ 95,713
Marketable securities	142,917	206,117
Prepaid expenses and other current assets	9,200	9,161
Total current assets	228,665	310,991
Property and equipment, net	249	457
Other assets	3,048	3,136
Operating lease right-of-use assets, net	320	634
Total assets	232,282	315,218
Current liabilities
Accounts payable	10,058	12,945
Accrued expenses and other current liabilities	17,642	25,996
Current portion of operating lease liabilities	424	843
Total current liabilities	28,124	39,784
Commitments and contingencies (see Note 11)
Stockholders’ equity:
Preferred stock, $0.001 par value per share; 10,000,000 shares authorized; no shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively
Common stock, $0.001 par value; 300,000,000 shares authorized; 80,204,699 and 78,126,796 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively	80	78
Additional paid-in capital	805,116	797,751
Accumulated other comprehensive (loss) gain	(96)	174
Accumulated deficit	(600,942)	(522,569)
Total stockholders’ equity	204,158	275,434
Total liabilities and stockholders’ equity	$ 232,282	$ 315,218